BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35491322)

  • 21. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
    Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
    Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SMARCA4-deficient Sinonasal Carcinoma: A Series of 10 Cases Expanding the Genetic Spectrum of SWI/SNF-driven Sinonasal Malignancies.
    Agaimy A; Jain D; Uddin N; Rooper LM; Bishop JA
    Am J Surg Pathol; 2020 May; 44(5):703-710. PubMed ID: 31934917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives and Issues in the Assessment of
    Armon S; Hofman P; IliƩ M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
    Rekhtman N; Montecalvo J; Chang JC; Alex D; Ptashkin RN; Ai N; Sauter JL; Kezlarian B; Jungbluth A; Desmeules P; Beras A; Bishop JA; Plodkowski AJ; Gounder MM; Schoenfeld AJ; Namakydoust A; Li BT; Rudin CM; Riely GJ; Jones DR; Ladanyi M; Travis WD
    J Thorac Oncol; 2020 Feb; 15(2):231-247. PubMed ID: 31751681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
    Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
    [No Abstract]   [Full Text] [Related]  

  • 28. SWI/SNF-deficient thoraco-pulmonary neoplasms.
    Sesboue C; Le Loarer F
    Semin Diagn Pathol; 2021 May; 38(3):183-194. PubMed ID: 33451916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature.
    Yadav R; Sun L; Salyana M; Eric M; Gotlieb V; Wang JC
    J Investig Med High Impact Case Rep; 2022; 10():23247096221074864. PubMed ID: 35356840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
    Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
    J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytologic Features of SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Comparison with Other SWI/SNF Complex-Deficient Tumors.
    Matsushita M; Kuwamoto S
    Acta Cytol; 2018; 62(5-6):456-462. PubMed ID: 30286456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers.
    Tagal V; Wei S; Zhang W; Brekken RA; Posner BA; Peyton M; Girard L; Hwang T; Wheeler DA; Minna JD; White MA; Gazdar AF; Roth MG
    Nat Commun; 2017 Jan; 8():14098. PubMed ID: 28102363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
    Strehl JD; Wachter DL; Fiedler J; Heimerl E; Beckmann MW; Hartmann A; Agaimy A
    Ann Diagn Pathol; 2015 Aug; 19(4):198-202. PubMed ID: 25920939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors.
    Medina PP; Carretero J; Fraga MF; Esteller M; Sidransky D; Sanchez-Cespedes M
    Genes Chromosomes Cancer; 2004 Oct; 41(2):170-7. PubMed ID: 15287030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
    Tian Y; Xu L; Li X; Li H; Zhao M
    Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
    Xue Y; Meehan B; Fu Z; Wang XQD; Fiset PO; Rieker R; Levins C; Kong T; Zhu X; Morin G; Skerritt L; Herpel E; Venneti S; Martinez D; Judkins AR; Jung S; Camilleri-Broet S; Gonzalez AV; Guiot MC; Lockwood WW; Spicer JD; Agaimy A; Pastor WA; Dostie J; Rak J; Foulkes WD; Huang S
    Nat Commun; 2019 Feb; 10(1):557. PubMed ID: 30718506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.
    Chatzopoulos K; Boland JM
    Virchows Arch; 2021 Jan; 478(1):21-30. PubMed ID: 33409598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of SOX2 in the differential diagnosis of SMARCA4 (BRG1)-deficient uterine neoplasms.
    Zheng L; Zhang L; Wang XI; Katz G; Tandon N; Zhao B; Lucci J; Ding J; Zhang S
    Hum Pathol; 2022 Jun; 124():45-55. PubMed ID: 35331811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SMARCA4 (BRG1) and SMARCB1 (INI1) expression in TTF-1 negative neuroendocrine carcinomas including merkel cell carcinoma.
    Gandhi JS; Alnoor F; Sadiq Q; Solares J; Gradowski JF
    Pathol Res Pract; 2021 Mar; 219():153341. PubMed ID: 33581550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.